Tessera Therapeutics
Ersin Akinci is a Principal Scientist at Tessera Therapeutics since February 2022. Prior to this, Akinci held positions such as a Research Scientist at Harvard Medical School and Brigham and Women's Hospital, and Asst. Prof. Dr.-Group Leader at Akdeniz University Department of Biotechnology. With a background in Molecular Biology and Genetics, Akinci has led various research projects and initiatives in gene editing, CRISPR technology, and genome-wide screenings. Graduating with a PhD in Molecular Cellular Developmental Biology and Genetics, Akinci has a strong academic and research background.
Tessera Therapeutics
3 followers
Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.